KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得

A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Oral Anticoagulation in Systemic Sclerosis-Related Pulmonary Arterial Hypertension-Results From the SPHInX Study.

Mandana Nikpour, Alicia Calderone, Susanna M Proudman, Dylan Hansen, Eli Gabbay, Nathan Dwyer, Gregory Keir, Vivek Thakkar, Peter K K Wong, Anne Keogh, Andrew Burns, David Prior, Harshal Nandurkar, David S Celermajer, Joanne Sahhar, Rachelle Buchbinder, Wendy Stevens

Pulm Circ 16(2) e70331

PMID42266819
PMCIDPMC13244262
DOI10.1002/pul2.70331
发表日期2026-06-10
摘要

摘要

The SPHInX study is the first-ever randomized controlled trial (RCT) seeking to inform an area of equipoise regarding the efficacy of oral anticoagulation as adjunct therapy in systemic sclerosis-related pulmonary arterial hypertension (SSc-PAH). The SPHInX study was an Australian multicenter, double-blind Phase III RCT of 1:1 oral apixaban 2.5 mg twice daily versus placebo over 3 years, as additional therapy in patients with SSc-PAH. The primary end-point was time to clinical worsening (TtCW), or death. A sample size of 85 per arm was required to show a two-fold reduction in TtCW. Participants experiencing clinical worsening events continued in the study, allowing for assessment of exploratory endpoints (including physical function and quality of life measures) up until 3 years of treatment. Among 11 SSc-PAH participants assigned apixaban treatment and 14 participants assigned placebo, apixaban demonstrated no benefit compared to placebo for TtCW from commencement until 30 days after discontinuation of study drug, Cox proportional hazard ratio 0.92 (95% confidence interval 0.32-2.66), p = 0.88. There was no difference between treatment groups in event-free survival, all-cause mortality, or exploratory endpoints. New iron deficiency anemia occurred in 9 (81.8%) apixaban treated participants compared to 4 (28.6%) controls. Although strict selection criteria in a complex disease meant recruitment was insufficient for the primary efficacy endpoint, the SPHInX RCT showed no signal for benefit with anticoagulation as adjunct therapy, with a high frequency of iron deficiency anemia suggesting that even at low doses, risk may outweigh benefit with anticoagulation in SSc-PAH. Trial Registration: Australian New Zealand Clinical Trials Registry Registration Number: ACTRN12614000418673 (http://www.ANZCTR.org.au/ACTRN12614000418673.aspx).

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 3

Figure 3 Kaplan–Meier survival curves for time from commencement of treatment to primary endpoint by treatment allocation.

Clinical_worsening_event-free_survival

Clinical worsening event-free survival

Figure 3 · Panel Clinical_worsening_event-free_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Clinical_worsening_event-free_survival 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 SPHINX study assessment timeline. Over the course of 36 months study treatment, participants visited study sites at the following times post‐randomization: 1, 3, 6, 12, 18, 24, 30, and 36 months (*end of study visit, performed on the day of permanent cessation of study drug, sooner than 36 months in exceptional circumstances). Telephone follow‐up maintained monthly contact between scheduled visits in the first 12 months, occurring third‐monthly thereafter, until 30 days after the end of study visit ( † 37 months post‐randomization at the latest), to capture self‐reported compliance and health service utilization, in particular changes to concomitant medication, adverse event surveillance, and clinical worsening events. ‡ Performed at baseline, 6, and 24 months, clinical worsening event, and end of study visits. § Data obtained within 2 months of baseline, 6, and 24 months visits. || Storage at −80°C from baseline, 6, and 24 month visits, to be batch tested in a single laboratory at the end of study, for serum NT‐proBNP and plasma anti‐Factor Xa.
非 KM Figure
Figure 2Figure 2 Diagram depicting the flow of participants through each stage of the SPHInX study. bid = twice daily oral intake, EC = exclusion criteria, ETRA = endothelin‐1 receptor antagonist, IV = intravenous, PDE‐5 = phosphodiesterase type 5, PH = pulmonary hypertension, RHC = right heart catheterization, SAE = serious adverse event, SSc‐PAH = systemic sclerosis related pulmonary arterial hypertension.
非 KM Figure
Figure 4Figure 4 Multilevel mixed‐effects linear regression models of exploratory outcome measures. The marginal effect (95% confidence interval displayed by error bars) of the full interaction between treatment and time is displayed for each of the continuous exploratory outcomes: (A) Six minute walk distance in meters; (B) Borg dyspnea index on a scale from 0 Nothing at all , to 10 Very, very severe (maximal breathlessness); (C) PAH‐related symptomatic impairment up to a maximum of 25 points on the CAMPHOR; (D) CAMPHOR activity (disability) score, from a 15 item scale where 0 is able to do on their own without difficulty, 1 is able to do on their own with difficulty, and 2 is unable to do on own, such that worse disability reaches a maximum 30 points; (E) CAMPHOR overall quality of life scores negatively weighted to worsening, up to a maximum of 25 points; (F) Percentage of total possible SF‐36 physical component score;* (G) Percentage of total possible SF‐36 mental component scores;* (H) Total SHAQ Visual Analog Scale selections from 0 to 10, with 0 being no functional limitation and 10 being severe functional limitation , combined across six areas of SSc‐related limitation; (I) HAQ‐DI is the mean of 8 category scores from the 20‐item Sanford Health Assessment Questionnaire, a disability index where items are rated from 0 to 3, where higher scores indicate greatest disability. *SF‐36 component scores are averaged values from the physical and mental scales in the Medical Outcomes Study Short Form‐36, ranging from 0 to 100, where 0 is the presence of worst possible limitations and higher scores represent more favorable physical or mental health state.
非 KM Figure